Ozenoxacin (Dubine®) 10mg/g cream for the short term treatment of non-bullous impetigo in adults, adolescents, children, and infants aged 6 months and older.
|NCPE Assessment Process||Complete|
|Rapid review commissioned||12/11/2018|
|Rapid review completed||13/12/2018|
|Rapid Review outcome||A full HTA is not recommended. The NCPE recommends that ozenoxacin cream not be considered for reimbursement at the submitted price. This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.